

Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and Neighbourhood East (Washwood Heath PCN)

Document Number 410-1-ES

Date of Preparation Dec 2025

Project title	BSOL - LUCID Accelerate
Aims and Objectives	Aims: LUCID model implementation programme to identify chronic kidney disease (CKD) patients in primary care suitable for virtual management.Objectives: Risk stratify the CKD population of the 8 PCNs involved and subsequently improve clinical outcomes by bringing secondary care capability into primary care and implementing gold standard management. • Increase early identification of CKD patients suitable for virtual management. • Provide a community outreach service, enabling multidisciplinary team (MDT) at a PCN level, driving new models of care. • Improve the quality of care delivered to CKD patients by increasing the capability and confidence of primary care providers.
Anticipated benefits	For the Patients: Early diagnosis of patients living with CKD Improve access to optimal treatment in line with guideline recommended therapy leading to reduced likelihood of progression to end stage kidney disease (ESKD) and risk of cardiovascular events. This incorporates the concurrent treatment of clinical issues that present a barrier to achieving guideline-directed medical therapy (GDMT), including hyperkalaemia. Facilitate expedited referral to secondary care for very high-risk patients Improve patient experience (access to services by the provision of care closer to home, via a virtual setting, reduce the number of visits required in primary and secondary care, and duplication of tests) For the NHS: Improved service delivery Increased number of patients with CKD achieving guideline recommended therapy. This incorporates the concurrent treatment of clinical issues that present a barrier to achieving guideline-directed medical therapy (GDMT), including hyperkalaemia. Improved capability in managing CKD in primary care Reduce Advice and Guidance queries Identify high-risk patients for expedited referral Reduction in number of new patient clinic attendances For AstraZeneca UK: This project is in line with AstraZeneca's medical mission to reduce death and progression to ESKD in CKD To scale an impactful, cost effective and commissioned service model that improves CKD outcomes

	for patients and demonstrates value to the NHS. Better understanding of the challenges in national model implementation. AstraZeneca manufactures medicines for the treatment of heart failure, CKD, diabetes and hyperkalaemia and due to medicines optimisation, the prescribing of these medicines may increase. The project is not reliant upon prescribing of AstraZeneca medicines and the decision to prescribe will remain with the clinician in line with local protocols and guidelines.
Timeline	The project will commence on the 01 Jan 2026 and will continue for a duration of 13 months.
References	[References]